Frederick Askari, MD, PhD

Real-World Evidence and Strategies for Long-Term Adherence in Wilson Disease

In this episode, 'Real-World Evidence and Strategies for Long-Term Adherence in Wilson Disease,' the experts explore the complexities of maintaining treatment compliance in a lifelong chronic condition. Dr. Rima Fawaz addresses the "grave and irreversible" consequences of non-adherence, particularly for patients with neurological presentations. She notes a unique challenge in hepatic-focused cases, where a lack of daily symptoms can lead to a false sense of security, resulting in treatment gaps that may eventually trigger acute liver failure or decompensation. The panel specifically identifies the "desire to be normal" as a major hurdle for pediatric and adolescent patients, who often struggle with dietary restrictions and the social stigma of frequent medication.

The discussion shifts to a review of data from the AASLD Liver Meeting, which demonstrated a high medication adherence rate (84% of days covered) for patients treated with trientine tetrahydrochloride. Dr. Peter Hedera emphasizes that these findings are "data-driven" evidence that convenience directly correlates with clinical success. He highlights that removing technical barriers—such as the need for refrigeration or the shift from thrice-daily to twice-daily dosing—provides tangible benefits for students and active adults.

Concluding the segment, the panelists reflect on the psychological components of adherence, noting that even patients with medical backgrounds can relapse if they stop treatment because they "feel okay." The experts agree that while clinical trials establish efficacy, real-world evidence is essential for understanding how subtle changes in drug formulation can lead to profound improvements in long-term patient stability and quality of life.

The next episode in this series, 'The Multidisciplinary Approach to Patient Counseling and Care Transitions in Wilson Disease,' features the panelists advancing their conversation on Wilson disease and focusing on the essential role of longitudinal education. The experts discuss tailored counseling strategies to combat treatment burnout, the logistical hurdles of transitioning from pediatric to adult care, and how center-of-excellence models utilize multidisciplinary teams to prevent patients from falling through the cracks.

Videos

New ATP7B gene therapies aim to normalize copper in Wilson’s disease, reducing chelation needs while raising durability and patient-selection questions.

Gene Therapy as an Emerging Treatment Approach in Wilson Disease

This episode, titled 'Gene Therapy as an Emerging Treatment Approach in Wilson Disease,' features panelists discussing the revolutionary potential of UX701 and other AAV-based gene therapies. Dr. Peter Hedera explains that because carriers of a single ATP7B mutation are asymptomatic, a treatment does not need to achieve 100% expression to restore functional copper homeostasis. However, he raises critical questions regarding the durability of these benefits, noting that because hepatocytes are dividing cells, there is a risk of losing the genetic construct over time. Furthermore, the immunogenicity of adeno-associated viruses (AAV) typically limits patients to a single "one-shot" treatment, making durability the primary focus of current clinical trials.

The conversation expands into next-generation technologies like CRISPR-Cas9 and prime editing. While these tools offer the possibility of permanent genetic correction, the experts acknowledge the immense challenge posed by the high number of unique ATP7B mutations. The panelists emphasize that the future of Wilson disease management will likely move away from a "one size fits all" model toward a highly individualized approach. This could involve tailoring choices between traditional chelation, once-daily salts, or gene therapy based on a patient's lifestyle, their ability to adhere to complex regimens, and their willingness to undergo short-term immunosuppression for long-term freedom from daily pills.

As the segment concludes, the panel highlights that while current trials often focus on stable patients, future research may investigate whether gene therapy can accelerate recovery in acutely ill or non-compliant populations. The experts look forward to real-world evidence to determine if these emerging therapies will act as standalone cures or be integrated into hybrid treatment plans, marking an era of unprecedented granular control in medical genetics.

In the next episode, 'Real-World Evidence and Strategies for Long-Term Adherence in Wilson Disease,' panelists will continue their discussion on Wilson disease and highlight the critical barriers to lifelong medication compliance. The experts examine recent real-world data regarding treatment discontinuation and discuss how practical factors—such as dosing frequency and storage requirements—significantly influence clinical outcomes and disease progression.

Multidisciplinary Symptom Management and Strategies for Modifying Therapy in Wilson Disease

In 'Multidisciplinary Symptom Management and Strategies for Modifying Therapy in Wilson Disease,' our panel delves into the comprehensive care models required for patients who do not achieve a full reversal of symptoms through copper-clearing therapy alone. Dr. Peter Hedera highlights the importance of the Unified Wilson’s Disease Rating Scale (UWDRS) for monitoring the emergence of new symptoms, such as tremor or balance issues, which can signal non-compliance, over-treatment, or evolving complications like myelopathy. For patients with medically refractory symptoms, the panel explores adjunctive interventions, including beta-blockers, botulinum toxin for focal dystonia, and even deep brain stimulation (DBS) for severe cases.

The discussion also addresses the management of decompensated cirrhosis and the controversial use of liver transplantation for acute neurological patients who do not respond to medication. While a transplant can restore copper homeostasis, the experts caution that it exchanges one set of challenges for another, including lifelong immunosuppression. Dr. Rima Fawaz emphasizes the critical role of non-pharmacological interventions—specifically physical, occupational, and speech therapy—to help re-educate damaged neurons as copper levels stabilize.

The final segment of the episode identifies several critical unmet needs in current Wilson disease management. These include the difficulty of monitoring pediatric patients during intercurrent illnesses, the lack of liquid formulations for chelators, and the urgent need for a commercially available, reliable assay for non-ceruloplasmin-bound copper to more accurately track compliance. The experts conclude by looking forward to upcoming trials for trientine tetrahydrochloride, which are investigating once-daily dosing and initial treatment protocols to further close these gaps in care.

Our next episode, 'Gene Therapy as an Emerging Treatment Approach in Wilson Disease,' further explores Wilson disease, highlighting the shift toward restorative treatments that aim to correct the underlying genetic defect. The panelists discuss the potential for long-term copper control through investigational gene therapies and the promise of emerging gene-editing technologies to reduce or eliminate the need for lifelong medication.

How experts track Wilson disease symptoms, fine-tune chelation or zinc, and use tremor, dystonia therapies to protect quality of life.

Monitoring Treatment Response and Preventing Copper Insufficiency in Wilson Disease

In this episode, 'Monitoring Treatment Response and Preventing Copper Insufficiency in Wilson Disease,' the panelists explore the long-term management of Wilson disease through consistent biochemical and clinical evaluation. Dr. Rima Fawaz outlines a monitoring schedule that begins with weekly checks to screen for early adverse events, transitioning to monthly and then quarterly assessments during the first year of therapy. Key laboratory markers include liver enzymes, INR, ceruloplasmin, and 24-hour urine copper collections, which serve as critical indicators of both disease control and patient adherence.

The discussion also highlights the risk of iatrogenic copper insufficiency—a "canary in the coal mine" scenario where over-treatment leads to new clinical complications. Dr. Peter Hedera identifies neutropenia and unexplained anemia as sentinel laboratory signs of impending copper deficiency, often appearing before neurological symptoms like myelopathy or ataxia manifest. The experts emphasize the importance of monitoring the complete blood count (CBC) and iron studies, as copper is essential for proper iron metabolism; thus, a copper-deficient state can paradoxically present as high ferritin levels or secondary iron deficiency.

Finally, the panel addresses the practical challenges of monitoring adherence in pediatric and adolescent populations. Dr. Fawaz notes that low 24-hour urine zinc levels often suggest that the medication is being taken with food, which impairs absorption. To overcome these lifestyle barriers, the experts suggest creative solutions, such as coordinating with school nurses for mid-day dosing. The episode concludes by reinforcing that while copper deficiency is more common in long-term adult patients, vigilant monitoring is required across all age groups to maintain the narrow therapeutic window between copper toxicity and deficiency.

The next episode in this series, 'Multidisciplinary Symptom Management and Strategies for Modifying Therapy in Wilson Disease,' features the panelists advancing their conversation on Wilson disease and focusing on the clinical nuances of managing persistent neurological and hepatic symptoms. The experts discuss the utility of standardized rating scales, the role of adjunctive symptomatic therapies, and the specific clinical triggers that warrant a switch in pharmacological regimens.

Frederick Askari, MD, PhD

Articles